Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid…
NCT00049712 · University of Wisconsin, Madison, Other · Completed
Key facts
| NCT number | NCT00049712 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma |
| Official title | A Phase I Study Of Medi 522 In Patients With Advanced Tumors |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | etaracizumab |
| Start date | Oct 1, 2002 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 13, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: